NATCO PHARMA LTD. is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 1,945 | 2,707 | 3,999 | 4,430 | 4,078 |
| EBITDA (ex other income) | 264 | 936 | 1,751 | 2,196 | 1,437 |
| margin % | 13.5 | 34.6 | 43.8 | 49.6 | 35.2 |
| Owners' profit | 170 | 715 | 1,388 | 1,885 | 1,419 |
| EPS, as reported (₹) | 9.32 | 39.18 | 77.34 | 105.26 | 79.20 |
| ROE % · ROCE % | 4.0 · 5.0 | 14.7 · 17.6 | 23.7 · 28.5 | 24.7 · 30.1 | 15.4 · 16.3 |
| Debt / equity (x) | 0.09 | 0.03 | 0.06 | 0.04 | 0.08 |
| Cash from operations | 47 | 849 | 1,212 | 1,697 | 1,768 |
| Capex | (233) | (146) | (339) | (401) | (388) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,371 | 475 | 1,221 | 1,329 | 1,363 | 647 | 739 | 735 |
| Profit before tax | 818 | 164 | 506 | 572 | 614 | 161 | 144 | 186 |
| Net profit | 677 | 132 | 406 | 480 | 518 | 151 | 269 | 207 |
| EPS (₹) | 37.81 | 7.43 | 22.70 | 26.84 | 28.94 | 8.46 | 14.96 | 11.53 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Pharmaceuticals | 3,940 | 96.6 |
| Agro chemicals | 110 | 2.7 |
| Agro Chemicals | 28 | 0.7 |
| Total, before eliminations | 4,078 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 9 Sept 2026 · NATCO Pharma files draft letter of offer for up to Rs 1,300 crore rights issue | corporate actions | high | — | — |
| 9 Sept 2026 · Natco Pharma approves up to INR 1,300 crore rights issue and demerger changes | corporate actions | high | — | — |
| 5 Sept 2026 · Newspaper Publication of 43rd AGM Notice | compliance | minimal | — | — |
| 4 Sept 2026 · Natco Pharma 43rd AGM on Sep 30; seeks nod to raise up to Rs 2,000 cr | board shareholder meetings | low | — | — |
| 4 Sept 2026 · Natco Pharma FY26 BRSR: 74 percent exports, ESG targets progress | compliance | low | — | — |
| 4 Sept 2026 · NATCO Pharma FY26 Annual Report: Rs 43,759 Mn Revenue, Rs 14,185 Mn PAT | results | high | — | — |
| 4 Sept 2026 · Natco Pharma Board to Consider Fund Raising on September 9 | fund raising | medium | — | — |
| 2 Sept 2026 · Natco Pharma to attend investor meet on Sept 7 in Hyderabad | board shareholder meetings | low | — | — |
| 26 Aug 2026 · Promoter gifts 50,000 shares to niece via off-market transfer | ownership changes | low | — | — |
| 25 Aug 2026 · Natco to invest US$14 million in eGenesis | strategic transactions | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| DIVI S LABORATORIES LTD |
| 2,47,033 |
| 84.6 |
| 14.74 |
| 63.7 |
| 15.3 |
| 18.8 |
| 8.7 |
| 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 12.8 | 28.9 | 34 of 169 | 80% |
| P/B | 1.6 | 3.3 | 38 of 163 | 77% |
| ROCE | 15.9 | 10.8 | 55 of 183 | 70% |
| ROE | 15.4 | 10.4 | 49 of 171 | 72% |
| Debt / Equity | 0.1 | 0.1 | 79 of 171 | 54% |
| EBITDA margin | 33.4 | 17.5 | 22 of 165 | 87% |
| Revenue growth | (44.7) | 16.3 | 153 of 161 | 5% |
| Profit growth | (57.0) | 30.9 | 136 of 158 | 14% |
| Market cap | 14615 | 839 | 39 of 182 | 79% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
